<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39348613</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2687-8941</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JCO global oncology</Title><ISOAbbreviation>JCO Glob Oncol</ISOAbbreviation></Journal><ArticleTitle>Impact of the Early Phase of the COVID-19 Pandemic on the Quality of Care for Colorectal and Anal Cancers at Comprehensive Cancer Centers on Two Continents.</ArticleTitle><Pagination><StartPage>e2400037</StartPage><MedlinePgn>e2400037</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/GO.24.00037</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The early phase of the COVID-19 pandemic affected cancer care globally. Evaluating the impact of the pandemic on the quality of cancer care delivery is crucial for understanding how changes in care delivery may influence outcomes. Our study compared care delivered during the early phase of the pandemic with the same period in the previous year at two institutions across continents (Princess Margaret Cancer Center [PM] in Canada and A.C. Camargo Cancer Center [AC] in Brazil).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients newly diagnosed with colorectal or anal cancer between February and December 2019 and the same period in 2020 were analyzed. Sociodemographic and clinical characteristics and performance of individual indicators within and between centers and between the peri-COVID-19 and control cohorts were tested using Cohen's <i>h</i> test to assess the standardized differences between the two groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 925 patients, distinct effects of the early COVID-19 pandemic on oncology services were observed. AC experienced a 50% reduction in patient consultations (98 <i>v</i> 197) versus a 12.5% reduction at PM (294 <i>v</i> 336). Similarly, AC experienced a higher proportion of stage IV disease presentations (42.9% <i>v</i> 29.9%; <i>P</i> = .015) and an increase in treatment delay (61.9% <i>v</i> 9.7%; <i>P</i> &lt; .001) compared with prepandemic. At PM, a 10% increase in treatment interruption (32.4% <i>v</i> 22.3%; <i>P</i> &lt; .001) and a higher rate of discontinuation of radiotherapy (9.4% <i>v</i> 1.1%; <i>P</i> &lt; .001) were observed during the pandemic. Postsurgical readmission rates increased in both AC (20.9% <i>v</i> 2.6%; <i>P</i> &lt; .001) and PM (10.5% <i>v</i> 3.6%; <i>P</i> &lt; .01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The early phase of the COVID-19 pandemic affected the quality of care delivery for colorectal and anal cancers at both centers. However, the magnitude of this impact was greater in Brazil.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saldanha</LastName><ForeName>Erick F</ForeName><Initials>EF</Initials><Identifier Source="ORCID">0000-0001-7972-4244</Identifier><AffiliationInfo><Affiliation>A.C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powis</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6038-0701</Identifier><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Divya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biostatistics Division, Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espin-Garcia</LastName><ForeName>Osvaldo</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2052-2626</Identifier><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics Division, Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology and Biostatistics, Western University, London, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dalla Lana School of Public Health and Statistical Sciences, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hack</LastName><ForeName>Saidah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalher</LastName><ForeName>Felicia</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0007-8835-1081</Identifier><AffiliationInfo><Affiliation>A.C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Maria Rita</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>A.C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simoes</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>A.C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huaqi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3335-7500</Identifier><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baiad</LastName><ForeName>Abed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohmand</LastName><ForeName>Zuhul</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakhla</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8479-9224</Identifier><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguiar</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>A.C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riechelmann</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0107-9617</Identifier><AffiliationInfo><Affiliation>A.C. Camargo Cancer Center, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krzyzanowska</LastName><ForeName>Monika K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0001-5533-7418</Identifier><AffiliationInfo><Affiliation>Cancer Quality Lab (CQual), Princess Margaret Cancer Centre, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Glob Oncol</MedlineTA><NlmUniqueID>101760170</NlmUniqueID><ISSNLinking>2687-8941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="Y">Anus Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011787" MajorTopicYN="Y">Quality of Health Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002173" MajorTopicYN="Y">Cancer Care Facilities</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39348613</ArticleId><ArticleId IdType="doi">10.1200/GO.24.00037</ArticleId></ArticleIdList></PubmedData></PubmedArticle>